News

The increasing prevalence of knee OA heightens the urgency of the search for effective therapies.

However, the degree to which biosimilars will drive down the cost of biologic therapy remains to be seen.

Good management of rheumatoid arthritis may also prevent serious infection, myocardial infarction, and even death related to comorbid disease.

The EULAR definition of arthralgia suspicious for progression to RA was recently validated.

Post-treatment Lyme disease syndrome is a real disorder with real symptoms, say researchers.

Abnormalities in the proportion of anti-inflammatory strains may represent a potential target for therapy.

Product may be contaminated with Salmonella.

Are you up-to-date on the latest EULAR/ACR classification criteria?

Monotherapy can lead to clinically inactive disease-but only in select patients.

How best to protect your patients at risk for fracture? Test your knowledge with this 10-question quiz.

Be vigilant for the development of type 2 diabetes in patients with systemic lupus erythematosus.

Complete remission remains an elusive goal.

A green light for dosing to achieve the target urate level.

There were decreased reports of pain when the patients believed treatment would work, and different brain regions were activated during real versus sham treatment.

Results of a recent meta-analysis fly in the face of established guidelines.

New data highlight the role of the C5a-C5aR axis in the onset of inflammation.

Moderate to high disease activity may persist.

In which patients with inflammatory back pain, does it make sense to repeat magnetic resonance scanning of the spine?

The implications for disease activity and quality of life when these disorders coexist.

Your encouragement has a measurable impact on your patients’ physical activity.

Drink up-but in moderation.

Do you have a case that can teach and inspire other clinicians?

The Biologics License Application is for another biosimilar to AbbVie's best-selling Humira drug.

Recently published EULAR/ACR classification criteria generally perform better than previous criteria.

A reliable biomarker linked to outcomes represents another step toward the goal of individualized treatment.

An accurate, inexpensive alternative for examining smaller joints is at hand.

No differences were observed in patellofemoral joint morphology between asymptomatic patients and those with pain.

High-risk patients, such as older women, are most likely to benefit.

Take reports of joint crepitus seriously, especially in older patients.

The trial is the first head-to-head clinical comparison in ankylosing spondylitis investigating the superiority of secukinumab for slowing spinal bone damage versus proposed biosimilar adalimumab.